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EDITORIAL
The  role of transbronchial  biopsy  in  the diagnosis  of diffuse
parenchymal lung  diseases:  Pro
O  papel  da  biopsia  transbrônquica  no  diagnóstico  das  doenc¸as difusas  do
parênquima  pulmonar:  Pró
The  diagnosis  of  diffuse  parenchymal  lung  disease  (DPLD)
may  require  invasive  procedures  after  all  noninvasive  tools
have  failed.  The  clinical  context  in  which  these  diseases
develop  and  the  radiological  patterns  are  crucial  for  deﬁning
the  timing  and  the  methods  to  be  used.  After  the  introduc-
tion  in  clinical  practice  of  High  Resolution  CT  scan  (HRCT),
the  evaluation  of  imaging  patterns,  along  with  the  immuno-
logical  status  of  the  patient  and  the  clinical  course  of  the
disease  (acute  vs.  chronic)  seem  to  be  crucial  in  choosing  the
best  diagnostic  procedure.1,2 In  the  immunocompromised
patients  who  develop  DPLD,  a  prompt  diagnosis  is  essential
for  a  better  survival.  In  this  circumstance,  bronchoalveolar
lavage  (BAL),  especially  when  the  bronchoscope  is  guided
by  HRCT  scan  ﬁndings  performed  a  few  hours  before,  is
generally  of  value  in  diagnosing  opportunistic  infections,
alveolar  proteinosis,  alveolar  hemorrhage  and  capillaritis,
lymphomatous  or  leukemic  lung  inﬁltration,  carcinomatous
lymphangitis,  disseminated  hematogenous  lung  metastases,
hypersensitivity  pneumonitis,  eosinophilic  pneumonitis  or
diffuse  alveolar  damage  due  to  drugs  or  radiation.  In  these
cases,  when  a  conclusive  diagnosis  is  not  obtained  by  BAL
ﬂuid  analysis  or  in  most  immunocompetent  patients  who
develop  DPLD,  transbronchial  lung  biopsy  (TBLB)  or  even
open  lung  biopsy  could  be  considered.  The  TBLB  forceps
makes  it  possible  to  obtain  lung  tissue  through  the  bronchial
routes  and  the  specimens  so  obtained  usually  represent
from  the  centrilobular  regions.3,4 Therefore,  the  disorders
that  are  centered  around  terminal  and  respiratory  bron-
chioles  [respiratory  bronchiolitis  (RB),  tuberculosis,  lobular
infectious  pneumonia,  cellular  bronchiolitis]  or  signiﬁcantly
involve  these  structures  (organizing  pneumonia)  or  are
distributed  along  the  lymphatic  routes  (sarcoidosis,  car-
cinomatous  lymphangitis)  may  be  frequently  sampled  by
the  forceps.4,5 In  1965,  Andersen  and  colleagues  at  the
Mayo  Clinic  described  for  the  ﬁrst  time  the  rigid  broncho-
scopic  technique  of  TBLB6 and  in  the  subsequent  trials  they
reported  that  lung  tissue  was  obtained  in  84%  of  patients
with  DPLD  by  using  the  technique  of  TBLB.7 The  introduc-
tion  of  the  ﬂexible  bronchoscope  in  the  late  1960s  increased
the  popularity  of  the  technique  and  demonstrated  that  TBLB
with  the  ﬂexible  instrument  may  be  obtained  with  minimal
mortality  and  morbidity.  Currently  TBLB  is  a  well-established
diagnostic  technique  used  by  almost  all  bronchoscopists,
and  the  ﬂexible  bronchoscope  is  used  almost  exclusively.
The  main  complication  of  TBLB  is  bleeding;  less  frequent
complications  are  pneumothorax,  hypoxemia,  or  cardiac
arrhythmias  during  the  procedure.  Bleeding  occurs  to  some
degree  in  virtually  all  TBLB  procedures  and  it  is  the  main
limiting  factor  in  obtaining  more  or  larger  biopsy  samples.
Bleeding  is  a  major  concern  to  the  bronchoscopist  because  of
the  limited  options  available  to  manage  excessive  bleeding
through  the  ﬂexible  bronchoscope.  The  suction  channel  of
the  typical  bronchoscope  is  only  2  mm  in  diameter,  and  the
volume  of  blood  that  can  be  suctioned  through  the  channel
is  therefore  limited.  However,  to  minimize  the  consequence
of  hemorrhage  by  TBLB,  it  is  possible  to  perform  the  proce-
dure  using  the  rigid  bronchoscopy  and  placing  a  non  inﬂated
Fogarty  balloon  and  a rigid  aspirator  (4  mm  in  diameter)  in
lobar  bronchus  near  the  biopsy  segment.  The  Fogarty  balloon
can  be  promptly  inﬂated  in  case  of  bleeding.  In  this  way  it
is  much  easier  to  control  the  bleeding  complications.8,3 The
main  utility  of  the  TBLB  rests  in  the  possibility  of  making  a
speciﬁc  diagnosis  in  a  patient  with  DPLD  and  avoiding  a  sur-
gical  lung  biopsy.  Some  studies  have  demonstrated  that  the
morphologic  ﬁndings  of  interstitial  inﬂammation  and  ﬁbro-
sis  in  TBLB  (such  as  in  the  diagnosis  of  idiopathic  interstitial
pneumonia)  appeared  to  have  little  relevance  to  subse-
quent  clinical  course.9 While  the  monomorphous  histological
patterns  (organizing  pneumonia,  eosinophilic  pneumonia,
diffuse  alveolar  damage  with  or  without  eosinophils,  alve-
olar  hemorrhage  with  or  without  capillaritis,  alveolar
proteinosis)  are  easily  identiﬁable  in  small  lung  fragments
(but  only  in  agreement  with  clinical,  radiological  and  other
laboratory  data),4,10 the  tiny  specimens  obtained  by  TBLB
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may  not  be  sufﬁcient  to  deﬁne  the  histological  pattern
(usual  interstitial  pneumonitis,  desquamative  interstitial
pneumonitis,  nonspeciﬁc  interstitial  pneumonitis,  ﬁbros-
ing  type).  However,  from  the  morphological  point  of  view,
generous  TBLB  may  also  provide  good  specimens  for  a diag-
nosis  of  a  pattern  called  nonspeciﬁc  interstitial  pneumonia
(NSIP),  cellular  variant  in  speciﬁc  clinical  settings  such  as
polymyositis-dermatomyositis-related  interstitial  lung  dis-
ease,  drug  toxicity  ore  in  cases  of  unknown  etiology11
although  surgical  lung  biopsy  is  considered  the  best  way
to  obtain  enough  tissue  to  demonstrate  this  pattern.  The
question  of  which  kind  of  biopsy  should  be  performed  to
diagnose  DPLD  has  a  long  and  controversial  history.  Cer-
tainly,  the  surgical  lung  biopsy  provides  substantially  more
material  for  pathological  study,  but  the  procedure  requires
general  anesthesia,  and  one  or  more  days  in  the  hospi-
tal  with  a  chest  tube  in  place.  Moreover,  some  reports
have  shown  that  this  surgical  procedure  may  be  associated
with  increased  mortality  in  certain  states  of  the  disease.
In  the  experience  of  many  interstitial  lung  disease  centers
across  the  world  the  median  mortality  is  4-6%  within  30
days  following  surgical  lung  biopsy  for  UIP12,13 but  biopsy
performed  at  the  time  of  acute  exacerbation  (AE)  resulted
in  higher  30-day  mortality  (28.6%)  compared  to  non-AE.14
Therefore,  in  recent  years  some  studies  have  sought  to
increase  the  diagnostic  yield  of  transbronchial  lung  biopsy
in  diagnosis  of  DPLD  to  avoid  the  surgical  lung  biopsy.  In
this  respect,  Berbescu  et  al15 reviewed  22  patients  with
known  UIP  (21  cases  diagnosed  by  surgical  biopsy,  1  case
diagnosed  by  clinical  and  radiologic  features)  and  then  ret-
rospectively  examined  transbronchial  biopsies  (TBLB)  from
these  patients.  They  concluded  that  a  diagnosis  of  UIP  was
possible  on  the  TBLB  in  seven  subjects,  and  in  two  others
that  the  ﬁndings  were  consistent  with  UIP.  As  a  rationale
for  the  use  of  TBLB,  the  authors  reported  the  high  mor-
tality  within  30  days  following  surgical  lung  biopsy  for  UIP.
However  in  a  critical  editorial  Churg  and  Schwarz  dampened
this  enthusiasm  and  suggested  that  ‘‘the  collective  wisdom
be  followed  and  that  TBLB  should  not  be  used  to  diagnose
IPF/UIP’’  because  the  morphologic  ﬁndings  of  interstitial
Figure  1  Transbronchial  lung  biopsy.  Diagnosis:  Carcinomato-
sus lymphangitis  due  to  gastric  adenocarcinoma.  The  lymphatics
are dilated  and  surrounded  by  neoplastic  acini.  Pulmonary
artery neoplastic  microangiopathy  is  also  present.
Figure  2  Transbronchial  lung  biopsy.  Intraalveolar  ﬁbrotic  bud
typically  observed  in  cryptogenetic  organizing  pneumonia.
inﬂammation  and  ﬁbrosis  in  TBLB  appeared  to  have  lit-
tle  relevance  to  the  subsequent  clinical  course.16 However
that  has  not  stopped  the  tenacity  of  other  researchers  in
assessing  the  improved  diagnostic  yield  using  non-surgical
methods  for  the  histological  diagnosis  of  ﬁbrosing  diffuse
lung  disease.  In  a  study,8 we  reported  a signiﬁcant  diag-
nostic  yield  and/or  better  preserved  specimens  (Fig.  1,  2)
when  TBLB  were  performed  under  general  anesthesia  with
rigid  bronchoscope  using  larger  forceps  (called  Jumbo  for-
ceps)  (Fig.  3)  and  without  pulling  them  through  the  biopsy
channel.  Then  a  new  way  of  obtaining  TBLB  using  ﬂexi-
ble  cryoprobes  was  recently  proposed  (Fig.  4a,  b,  c).  The
cryosurgical  equipment  operates  by  the  Joule-Thompson
effect,  which  dictates  that  a  compressed  gas  released  at
Figure  3  Jumbo  forcep  with  a  lung  sample  that  is  poured  out
of the  tip  of  the  forceps.
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Figure  4  (a)  A  ﬂexible  cryoprobe  is  shown.  The  metal  tip,  can  be  visualized  under  ﬂuoroscopic  control.  (b)  Transbronchial  lung
biopsy obtained  by  ﬂexible  cryoprobes  with  lung  sample  attached  to  the  metal  tip.  (c)  Hematoxylin  Eosin  (low  power).  Large
specimens showing  a  bronchiole  and  lung  parenchyma  (interstitial  inﬂammation;  preserved  lung  architecture).
high  ﬂow  rapidly  expands  and  creates  a  very  low  tempera-
ture.  The  advantage  of  the  cryoprobe  is that  large  pieces  of
tissue  can  be  extracted  with  the  freeze-thaw  cycle.  The  ﬁrst
published  data17,18 indicate  that,  especially  in  idiopathic
interstitial  pneumonia,  transbronchial  cryobiopsy  could  add
important  information.  The  size  of  the  samples  obtained
seems  to  increase  the  diagnostic  yield  signiﬁcantly  com-
pared  to  forceps  biopsies.  Transbronchial  cryobiopsies  are
much  larger  than  conventional  forceps  biopsies  but  smaller
than  surgical  lung  biopsies.  Despite  having  a  potentially
large  defect  in  the  lung  parenchyma,  the  occurrence  of
pneumothorax  and  bleeding  was  low  compared  to  data  from
forceps  biopsies.  These  data,  therefore,  indicate  that  the
TBLB  may  have  even  greater  potential  role  in  the  diagnostic
algorithm  of  DLDL  (even  in  its  ﬁbrosing  variants).
Furthermore,  when  TBLB  was  introduced  into  clinical
practice,  a  positive  biopsy  by  the  TBLB  technique  was
deﬁned  as  diagnostic  histology,  histology  that  supported  a
diagnosis,  or  histology  consistent  with  the  ﬁnal  diagnosis.
Indeed,  most  of  the  published  reports  have  focused  on  the
diagnostic  accuracy  of  histologic  analysis  of  TBLB  in  patients
with  diffuse  lung  disorders.  In  contrast  there  were  no  data
on  how  TBLB  results  are  used  by  clinicians.  In  a  very  interest-
ing  study,  Ensminger  and  Prakash19 evaluated  if  the  results
of  the  TBLB  were  clinically  useful  in  the  management  of
patients  with  diffuse  pulmonary  disorders.  In  the  study  TBLB
was  considered  useful  if:  (a)  it  resulted  in  a  speciﬁc  clini-
cal  diagnosis,  (b)  a  speciﬁc  management  decision  was  made
based  on  the  biopsy  result,  or  (c)  certain  pathologic  pro-
cesses  were  excluded  on  the  basis  of  the  biopsy  result  and
other  clinical  information.  The  results  indicated  that  TBLB  is
a  clinically  useful  test  in  approximately  75%  of  procedures,
certainly  not  a  negligible  percentage.
In  view  of  the  above  data,  we  believe  that  the  use  of  TBLB
in  the  diagnosis  of  DLDL  is  useful  and  safe,  but  certainly  still
too  underestimated  and  undervalued  by  most  clinicians.  We
believe  that  a  future  topic  in  the  study  of  DPLD  should  be  a
greater  implementation  of  the  techniques  of  immunohisto-
chemistry,  molecular  biology  and  microarray  to  be  applied
even  on  tiny  samples  obtained  from  the  TBLB  to  increase
the  diagnostic  yield  and  reduce  the  need  to  refer  to  surgical
lung  biopsy  for  diagnosis.
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